A new, innovative dermatology CME event!
Maui Derm Virtual Congress
Live-Stream Virtual Meeting • June 24-27, 2020 (CME)
Q&A Webinar • June 28, 2020 (non-CME)
REGISTRATION IS CLOSED
Only $99 tuition fee for entire Virtual Congress! Designed for the entire community of dermatology health care professionals. Earn up to 29.25 AMA PRA Category 1 Credits™. Bonus on-demand access to lectures for up to 2 months! Live-stream lectures with real-time commentary and Q&A. A world-class faculty sharing knowledge and techniques. A bonus day of Q&A Webinars to ask faculty your most pressing questions. A safe alternative to live, in-person CME conferences.
A four-day, COVID-19-safe, dermatology CME conference for only $99, including:
- Live-stream lectures from June 24-27 with presenters on-screen providing real-time commentary and Q&A with attendees. (CME)
- Designed for the entire community of dermatology health care professionals, including dermatologists and dermatology NPs and PAs.
- A bonus Q&A Webinar series on Sunday, June 28 to address your most pressing questions from the Virtual Congress. (non-CME)
- Plus, On-Demand Access to all lectures and workshops, at any time, for up to 2 months. (non-CME)
- Broadcast with state-of-the-art technology assuring video and audio quality.
- Earn up to 29.25 AMA PRA Category 1 Credits™ during live-stream event.
- Lectures and workshops from our world-class faculty.
- Virtual exhibit halls and product theaters featuring top companies in the industry.
- A safe alternative to a live, in-person CME conference.
Due to the COVID-19 pandemic and concern for the health and safety our meeting attendees, faculty, and industry representatives, coupled with the uncertainty of travel restrictions, this meeting is being conducted in lieu of our live meetings through summer 2020.
In support of improving patient care, this activity has been planned and implemented by Dannemiller and Advances in Cosmetic and Medical Dermatology. Dannemiller is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Dannemiller has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 29.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Dannemiller designates this educational activity for 29.5 contact hours, which includes 10.5 pharmacotherapeutic hours.
Overall Learning Objectives
- Review the pathogenesis of various dermatological conditions such as infectious diseases, psoriasis, psoriatic arthritis, acne vulgaris, rosacea, hidradenitis, contact dermatitis, atopic dermatitis, eczema, pruritus, actinic keratoses, melanoma and non-melanoma skin cancer, pediatric skin disorders, immunobullous diseases, granulomatous disorders of the skin, connective tissue diseases, hair and nail disorders, leg ulcers, oral lesions and life-threatening dermatoses such as TEN in order to accurately diagnose and improve upon the management of these conditions in patients
- Cite the mechanisms of action of various drugs, including topical and systemic therapies, as well as immunomodulatory agents that are commonly prescribed by the nurse practitioner and physician assistant practicing in dermatology and identify patients in your practice for whom these therapies may be appropriate
- Define appropriate outcome measures for the optimal follow-up of patients with dermatologic diseases as well as those receiving surgical and cosmetic procedures in order to set realistic expectations and maximize therapeutic outcomes
- Describe potential adverse events, safety, tolerance and resistance issues that may be related to the use of various drugs and therapies prescribed by clinicians in dermatology as well as therapeutic modalities including: topical and systemic corticosteroids, newer biologic agents, including TNF antagonists, T-cell and B-cell targeted therapies, anti-IL-12/23 therapies, IL-23 & IL-17 antibodies, systemic and topical PDE4 inhibitors, JAK inhibitors, anti-IgE and anti-IL 4 receptor, systemic retinoids, methotrexate, cyclosporine, neurokinin-1 receptor antagonists, systemic and topical acne/rosacea therapies, oral and topical antibiotics, antifungals, anti-viral therapies, wound healing agents, antihistamines, calcineurin inhibitors, topical skin lightening agents, sunscreens, topical and systemic retinoids, 5-fluorouracil, imiquimod, ingenol mebutate, diclofenac, photodynamic therapy, hedgehog pathway inhibitors, rituximab, BRAF/MEK inhibitors, CTLA-4 and PD-1/PDL-1 inhibitors, botulinum toxins, dermal filler agents including hyaluronic acid, collagen, polylactic acid, hydroxyappetite based fillers, and implement appropriate management strategies in order to reduce these adverse effects and optimize patient outcomes
- Assess the data around emerging and novel therapeutics for a variety of dermatologic diseases and develop treatment algorithms and management strategies for the optimal use of these therapies
- Discuss the importance of clinician/patient communication regarding benefit versus risk, patient satisfaction, and adherence when selecting therapies for patients